Drug Profile
Research programme: drug discovery - BioFocus/Boehringer Ingelheim
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator BioFocus DPI; Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Undefined in Belgium
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 20 Nov 2013 Early research in Undefined indication in Belgium (unspecified route)